Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon May 10, 2018 11:15am
214 Views
Post# 28011561

HELLO ANDRE...PLEASE TELL US WE ARE INVOLVED SOMEHOW !!!

HELLO ANDRE...PLEASE TELL US WE ARE INVOLVED SOMEHOW !!!ABOUT TIME CANADA NATIONAL SCREENIG PROGRAM... ADK WE HAVE THE SOFTWARE ! AND LOTS OF CONNECTIONS TO MONTREAL SCHOOL...

Expanding Diabetic Retinopathy Screening in Canada using Artificial Intelligence: A new collaboration supported by Diabetes Action Canada, the University of Montreal and The Montreal Polytechnique

By admin - May 8, 2018 10:36 am

 

Diabetes is considered a global epidemic, affecting 8.5% of the worldwide adult population . By 2020, 10% of the Canadian population will be living with diabetes. Those with the disease have an elevated risk of eyesight deterioration, which is the leading cause of blindness in adults under 60 years of age (working age).  Diabetic Retinopathy (DR) is a complication of diabetes and accounts for 80% of diabetic-related blindness.  Early detection of DR by regular screening effectively avoids vision loss from diabetes as necessary treatments prevent irreversible retina damage.

Diabetes Action Canada recognizes DR screening as a top priority. This prevention measure is shared amongst provincially funded telehealth and health authorities that are establishing DR screening programs to reach under-served and vulnerable populations.  Telehealth retinal screening programs have the potential to scale up as part of a broader population-based screening program. To accomplish this, diagnostic capacity constraints among Canadian ophthalmologists must be considered.  To address this, Diabetes Action Canada is now collaborating with a group of investigators at the University of Montreal (U of M), Department of Ophthalmology and The Montreal Polytechnique, who collaborate with the Montreal Institute for Learning Algorithms (MILA).  MILA is a federation of University of Montreal researchers focused on machine learning and artificial intelligence-based analytics.  With funding from Diabetes Action Canada and the U of M, they plan to develop algorithms using advanced technology to read retinal fundus photo images and optical coherence tomography (OCT) images for diagnosis of diabetic retinopathy and other eye disease. The fundamental goal is to improve access to high quality ophthalmological care by reducing image reading times and increasing clinician productivity.  Together, Diabetes Action Canada and U of M are interested in investigating the role of artificial intelligence (AI) in retinal image analytics and its potential for application in clinical contexts in Canada and beyond. Following algorithm development and validation, this group envisions creating a national consortium that could leverage advanced technology to deliver high-value retinal and OCT image analysis across Canada.

This research collaboration was recently featured in and article in Le Journal de Quebec found here.




Bullboard Posts